{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"description":"Number of patients who demonstrate a complete or partial response as defined below:\n\nComplete Response - Complete disappearance of all known disease for at least 4 weeks;\n\nPartial Response - A reduction of at least 50% in the size of all measurable tumor as quantitated by the sum of the products of the largest diameters of measurable lesions when compared with that measurement at the time of study enrollment and maintained for at least 4 weeks.","groups":[{"description":"Patients receive low-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.\n\nLenalidomide: Given PO\n\nPharmacological Study: Correlative studies","id":"OG000","title":"Arm I (Low-dose Lenalidomide)"},{"description":"Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.\n\nLenalidomide: Given PO\n\nPharmacological Study: Correlative studies","id":"OG001","title":"Arm II (High-dose Lenalidomide)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only eligible patients are considered in the analysis of this outcome measure","reportingStatus":"POSTED","timeFrame":"26 cycles of chemotherapy - up to 3 years after enrollment","title":"Number of Patients Who Demonstrate Complete or Partial Response","type":"PRIMARY","unitOfMeasure":"Participants"}